Heart attack damage slashed with micro particle therapy
First therapy to target damage after heart attack could transform field. After a heart attack, much of the damage to the heart muscle is caused by inflammatory cells… read more.
First therapy to target damage after heart attack could transform field. After a heart attack, much of the damage to the heart muscle is caused by inflammatory cells… read more.
Researchers found a novel approach to predict outcomes in heart failure patients by imaging impaired energy metabolism in a diseased heart. Researchers have identified a new method to… read more.
by Bruce Sylvester – While early stem cell transplantation in patients with aggressive non-Hodgkin’s lymphoma does not improve overall survival in intermediate/high-risk patients, early transplantation appears to be… read more.
by Bruce Sylvester – While early stem cell transplantation in patients with aggressive non-Hodgkin’s lymphoma does not improve overall survival in intermediate/high-risk patients, early transplantation appears to be… read more.
by Bruce Sylvester – Diflunisal, a generic anti-inflammatory drug, appears to reduce neurological decline and preserve quality-of-life in patients with familial transthyretin amyloidosis (ATTR).
Bernhard Banas, Regensburg, Germany – Prolonged-release tacrolimus administered once-daily provides high rates of graft survival and reduction in biopsy-confirmed acute rejection (BCAR), with a manageable tolerability profile, in patients… read more.
by Pavel Trunečka, Prague, Czech Republic – Starting on a low dose of prolonged-release, once-daily tacrolimus after liver transplantation achieved better renal function and a significantly lower risk… read more.
Re-transplantation is the only option available for salvaging a failed abdominal graft. As the outcomes after primary transplantations continue to improve, even with the increasing use of extended-criteria… read more.
Heinrich Schima, Vienna, Austria – In the last decades, ventricular-assist devices (VADs) – artificial hearts – have gone from pioneering experiments to offering a real alternative to heart… read more.
Invasive microbial infections are a major cause of morbidity and mortality in organ transplantation patients. The satellite symposia sponsored by Astellas Pharma at ESOT 2013 discussed the challenge… read more.
by Peter Friend, Oxford, UK – The 16th ESOT Congress in Vienna 2013 was one of ESOT’s most comprehensive arrangements to date, with more than 3,500 attendees and… read more.
Randall Morris, San Francisco, USA – Failure to make therapeutic progress is a real challenge in the transplantation field. On the face of it, the goals set up… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.